Kristi Rosa


FDA updates label for mitomycin gel in UTUC

September 29, 2022

The FDA has updated the label for mitomycin-containing reverse thermal gel (Jelmyto) in low-grade upper-tract urothelial cancer by extending the in-use period for pyelocalyceal solution admixture.

Olaparib falls short as add-on to durvalumab in mUC, but combo may benefit HRR+ subgroup

February 19, 2022

BAYOU trial results showed no significant PFS boost in all-comer population with addition of olaparib to frontline durvalumab in metastatic urothelial carcinoma, but potential benefit for combo was observed in HRR-mutation–positive subgroup.